BIOMAT Database Logo BIOMAT Database Logo

Kinetic study of antifungal activity of amphotericin B, 5-fluorocytosine and ketoconazole against clinical yeast isolates using liquid-phase turbidimetry. 1991

E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Laboratoire de Parasitologie, Centre Hospitalier Universitaire, Lille, France.

The fungal growth of clinical yeast isolates and of VW32 clone of Candida albicans were measured in vitro using a liquid-phase turbidimetric system (Bioscreen from Labsystems, France) in defined conditions. Cultures were performed in Shadomy's liquid medium and the fungal growth automatically evaluated every 10 minutes for 24 hours using various concentrations of drugs. The system made it possible to test 200 culture samples in one experiment. Yeast sensitivity to drugs was also measured by using our routine semi-automatic turbidimetric system. We observed that kinetic patterns of activity of each antifungal agent were typical. The in vitro tests showed that of 927 clinical yeast isolates 99.2% were sensitive to amphotericin B, 94.4% to 5-fluorocytosine and 69.7% to ketoconazole.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009391 Nephelometry and Turbidimetry Chemical analysis based on the phenomenon whereby light, passing through a medium with dispersed particles of a different refractive index from that of the medium, is attenuated in intensity by scattering. In turbidimetry, the intensity of light transmitted through the medium, the unscattered light, is measured. In nephelometry, the intensity of the scattered light is measured, usually, but not necessarily, at right angles to the incident light beam. Turbidimetry,Nephelometry,Turbidimetry and Nephelometry
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D005437 Flucytosine A fluorinated cytosine analog that is used as an antifungal agent. 5-Fluorocytosine,Alcobon,Ancobon,Ancotil
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D015003 Yeasts A general term for single-celled rounded fungi that reproduce by budding. Brewers' and bakers' yeasts are SACCHAROMYCES CEREVISIAE; therapeutic dried yeast is YEAST, DRIED. Yeast

Related Publications

E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
January 1991, Chemotherapy,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
January 1992, Chemotherapy,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.
June 1976, Antimicrobial agents and chemotherapy,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms.
November 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.
November 1982, Antimicrobial agents and chemotherapy,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole.
September 1982, The Journal of infectious diseases,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.
September 2008, Pharmaceutical research,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice.
September 1973, Antimicrobial agents and chemotherapy,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
[In vitro sensitivity of Aspergillus to terbinafine: comparative study on amphotericin B, 5-fluorocytosine and ketoconazole].
February 1988, Pathologie-biologie,
E Dei-Cas, and L Dujardin, and M E Ribeiro Pinto, and F Ajana, and J Fruit, and D Poulain, and D Camus, and A Vernes
Letter: Amphotericin B and 5-fluorocytosine.
October 1975, The Journal of infectious diseases,
Copied contents to your clipboard!